SCHEMBL22189337

SCHEMBL22189337

O=C(O)c1ccncc1Cc1ccccc1F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4C Q9H3R0 16/20 0.44
KDM6B O15054 7/20 0.44
KDM4D Q6B0I6 5/20 0.44
KDM4A O75164 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BRS3 P32247 1/20 0.42
EGLN3 Q9H6Z9 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
SGMS2 Q8NHU3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29581291 1.00 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10KDM4C
SCHEMBL22189659 0.83 ALDH1A1 (0.49) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL4951259 0.81 KDM4C (0.56) KDM4EALDH1A1KDM4CKDM6BKDM4D
SCHEMBL6390426 0.79 KDM4C (0.43) KDM4EALDH1A1HPGDHSD17B10KDM4C
SCHEMBL15818650 0.77 KDM4C (0.69) KDM4EKDM4CKDM6BKDM4DKDM4A
SCHEMBL22189609 0.77 KDM4C (0.45) KDM4EALDH1A1KDM4CKDM6BKDM4D
SCHEMBL29581046 0.77 KDM4C (0.45) KDM4EALDH1A1KDM4CKDM6BKDM4D
SCHEMBL11823508 0.75 DCLRE1B (0.46) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL28129596 0.74 TSHR (0.55) KDM4EALDH1A1HPGDHSD17B10KDM4C
SCHEMBL31132830 0.73 KDM4C (0.55) KDM4EALDH1A1KDM4CKDM6BKDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114126597-A Fibroblast activation protein inhibitor 普拉西斯生物技术有限责任公司 2022-03-01 CN disclosed
EP-3906024-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2021-11-10 EP disclosed
WO-2020142742-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2020-07-09 WO disclosed
US-20200216417-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2020-07-09 US disclosed
US-20200216417-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216417-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 KDM4E 3267/4885ALDH1A1 3702/4885HPGD 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.